# US 2021/0340617 A1 · Endometriosis-associated genetic markers predict responsiveness to leuprolide acetate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0340617 A1
- Document ID: US20210340617A1
- Status: Published application
- Kind: A1
- Application number: 17/282,258
- Filed: 2019-10-04
- Published: 2021-11-04
- Earliest claimed: 2018-10-04
- Assignees: Juneau Biosciences, LLC
- Applicants: Juneau Biosciences, L.L.C.
- Inventors: Kenneth WARD; VeeAnn ARGYLE; Peeches CEDERHOLM; Rakesh CHETTIER
- Web page: https://patentgrep.com/patent/US20210340617A1

## CPC

- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- C12Q 1/68: involving nucleic acids
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Disclosed herein are methods of using genetic variants to select for an effective treatment of endometriosis, for example via a computer-implemented program to predict responsiveness of a subject to a selected treatment, and methods of diagnosing endometriosis or a symptom thereof.

## Claims

### Claim 1

A method comprising:
(a) detecting a presence of at least one genetic variant of Table 1 in a genetic material obtained from a subject, wherein the subject has endometriosis or is at risk of developing endometriosis; and
(b) treating the subject for the endometriosis with a therapeutically effective amount of a treatment that comprises leuprolide acetate, a derivative thereof, a biosimilar thereof, or an interchangeable thereof.

### Claim 2

A method comprising:
(a) detecting a presence of at least one genetic variant of Table 2 in a genetic material obtained from a subject, wherein the subject has endometriosis or is at risk of developing endometriosis; and
(b) treating the subject for the endometriosis with a therapeutically effective amount of a treatment that does not comprise leuprolide acetate.

### Claim 3

A method comprising: detecting a presence of at least one genetic variant of Table 1 in a genetic material obtained from a subject, wherein the subject has endometriosis or is at risk of developing endometriosis, wherein the presence of the at least one genetic variant of Table 1 is indicative of a therapeutically effective response to a treatment for treating the endometriosis, and wherein the treatment comprises leuprolide acetate, a derivative thereof, a biosimilar thereof, or an interchangeable thereof.

### Claim 4

A method comprising: detecting a presence of at least one genetic variant of Table 2 in a genetic material obtained from a subject, wherein the subject has endometriosis or is a risk of developing endometriosis, wherein the presence of the at least one genetic variant of Table 2 is indicative of a therapeutically effective response to a treatment for treating the endometriosis, wherein the treatment does not comprise leuprolide acetate.

### Claim 5 (depends on 3)

The method of claim 3, further comprising: treating the subject for the endometriosis.

### Claim 6 (depends on 3)

The method of claim 3, wherein the treating comprises prophylactic treating.

### Claim 7 (depends on 3)

The method of claim 3, further comprising: altering or updating the treatment based at least in part on the detecting.

### Claim 8 (depends on 3)

The method of claim 3, wherein the detecting occurs prior to administering the treatment to the subject.

### Claim 9 (depends on 3)

The method of claim 3, further comprising: selecting the treatment from a plurality of treatments.

### Claim 10 (depends on 3)

The method of claim 3, further comprising: obtaining the genetic material from the subject.

### Claim 11 (depends on 3)

The method of claim 3, further comprising: providing a recommendation to prescribe the treatment to the subject.

### Claim 12 (depends on 3)

The method of claim 3, wherein the subject has the endometriosis.

### Claim 13 (depends on 3)

The method of claim 3, wherein the subject is at risk of developing the endometriosis.

### Claim 14 (depends on 3)

The method of claim 3, wherein the subject suffers from pelvic pain.

### Claim 15 (depends on 3)

The method of claim 3, wherein the subject suffers from infertility.

### Claim 16 (depends on 3)

The method of claim 3, wherein the genetic material is obtained from a reproductive tissue, a blood sample, or a combination thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the genetic material is obtained from the reproductive tissue that comprises endometrial tissue, uterine tissue, ovarian tissue, fallopian tissue, cervical tissue, vulvar tissue, or any combination thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the genetic material is obtained from the reproductive tissue that comprises the endometrial tissue.

### Claim 19 (depends on 16)

The method of claim 16, wherein the genetical material is obtained from the blood sample.

### Claim 20 (depends on 3)

The method of claim 3, wherein the genetic material comprises cell-free DNA.

### Claim 21 (depends on 3)

The method of claim 3, wherein the genetic material comprises RNA.

### Claim 22 (depends on 3)

The method of claim 3, wherein the genetic variant comprises at least two genetic variants.

### Claim 23 (depends on 3)

The method of claim 3, wherein the genetic variant is of MAP3K15.

### Claim 24 (depends on 3)

The method of claim 3, wherein the genetic variant is of C17orf53, MTL5, SYT15, BCO2, ADD1, C14orf79, or any combination thereof.

### Claim 25 (depends on 3)

The method of claim 3, wherein the detecting comprises sequencing at least a portion of the genetic material.

### Claim 26 (depends on 3)

The method of claim 3, wherein the detecting comprises hybridizing a probe to a portion of the genetic material, wherein the probe is specific for the genetic variant.

### Claim 27 (depends on 3)

The method of claim 3, further comprising: measuring a total variant burden in at least a portion of the genetic material.

### Claim 28 (depends on 3)

The method of claim 3, further comprising: measuring a mood of the subject.

### Claim 29 (depends on 3)

The method of claim 3, further comprising: measuring a hormone receptor level in the genetic material.

### Claim 30 (depends on 29)

The method of claim 29, wherein the hormone receptor level is an estrogen receptor level, a progesterone receptor level, or a combination thereof.

### Claim 31 (depends on 30)

The method of claim 30, wherein the hormone receptor level is the estrogen receptor level.

### Claim 32 (depends on 30)

The method of claim 30, wherein the hormone receptor level is the progesterone receptor level.

### Claim 33 (depends on 3)

The method of claim 3, wherein the treatment comprises administration of a gonadotropin releasing hormone (GnRH) or a synthetic analog thereof to the subject.

### Claim 34 (depends on 3)

The method of claim 3, wherein the treatment comprises administration of a GnRH receptor agonist, a GnRH receptor antagonist, a progestin, norethindrone, medroxyprogesterone, a biosimilar of any of these, an interchangeable of any of these, a salt of any of these, or any combination thereof.

### Claim 35 (depends on 3)

The method of claim 3, wherein the treatment comprises administration of RU-486 (CAS #84371-65-3), ethylnorgestrienone (CAS #16320-04-0), 2,3-isoxazolethisterone (CAS #17230-88-5), elagolix (CAS #834153-87-6), goserelin (CAS #65807-02-5), norethindrone acetate (CAS #38673-38-0), methylhydroxyprogesterone acetate (CAS #71-58-9), a biosimilar of any of these, an interchangeable of any of these, a salt of any of these, or any combination thereof.

### Claim 36 (depends on 3)

The method of claim 3, wherein the treatment comprises administration of a pharmaceutical composition in unit dose form.

### Claim 37 (depends on 3)

The method of claim 3, wherein the treatment comprises administration of a stem cell.

### Claim 38 (depends on 3)

The method of claim 3, wherein the treatment comprises administration of composition comprising: a cannabis, a nonsteroidal anti-inflammatory drug (NSAID), a progestin, a progesterone, or any combination thereof.

### Claim 39 (depends on 38)

The method of claim 38, wherein the composition comprises the cannabis, the NSAID, and the progestin.

### Claim 40 (depends on 38)

The method of claim 38, wherein the composition comprises the cannabis, the NSAID, and the progesterone.

### Claim 41 (depends on 38)

The method of claim 38, wherein the NSAID comprises ibuprofen, naproxen, or a combination thereof.

### Claim 42 (depends on 36)

The method of claim 36, wherein the composition further comprises human serum albumin.

### Claim 43 (depends on 3)

The method of claim 3, further comprising: comparing a result of the method to a reference.

### Claim 44 (depends on 43)

The method of claim 43, wherein the reference comprises a derivative of the reference.

### Claim 45 (depends on 43)

The method of claim 43, wherein the reference comprises a result of the method performed on a reference sample.

### Claim 46 (depends on 45)

The method of claim 45, wherein the reference sample is of a subject responsive to the treatment.

### Claim 47 (depends on 43)

The method of claim 43, wherein the comparing is performed by a computer processor.

### Claim 48 (depends on 43)

The method of claim 43, wherein the comparing is performed by a trained algorithm.

### Claim 49 (depends on 43)

The method of claim 43, wherein the reference comprises a result obtained from genetic material of a subject diagnosed with endometriosis.

### Claim 50 (depends on 43)

The method of claim 43, wherein the reference comprises a result obtained from genetic material of a subject responsive to the treatment.

### Claim 51 (depends on 3)

The method of claim 3, further comprising: detecting an epigenetic marker in at least a portion of the genetic material.

### Claim 52 (depends on 51)

The method of claim 51, wherein the epigenetic marker comprises a methylated marker, a hydroxymethylated marker, a carboxylated marker, a formylated marker, or any combination thereof.

### Claim 53 (depends on 51)

The method of claim 51, wherein the portion comprising the epigenetic marker is RNA or DNA.

### Claim 54 (depends on 3)

The method of claim 3, further comprising: reporting a result of the method.

### Claim 55 (depends on 54)

The method of claim 54, wherein the result comprises an output of the detecting.

### Claim 56 (depends on 54)

The method of claim 54, wherein the reporting comprises electronic reporting.

### Claim 57 (depends on 1)

The method of claim 1, further comprising: identifying the subject as a responder to the leuprolide acetate, the derivative thereof, the biosimilar thereof, or the interchangeable thereof.

### Claim 58 (depends on 2)

The method of claim 2, further comprising: identifying the subject as a non-responder to the leuprolide acetate.

### Claim 59 (depends on 57)

The method of claim 57, wherein the identifying is based in part on: a disease activity score; a presence, an absence, or a recurrence of pelvic pain; a cessation of the treatment; a scoring of dysmenorrhea; a presence of dyspareunia; a failure to conceive; a recurrence of a symptom following a treatment; a surgical intervention; or any combination thereof.

### Claim 60 (depends on 59)

The method of claim 59, wherein the identifying is based on the presence, the absence, or the recurrence of pelvic pain.

### Claim 61 (depends on 60)

The method of claim 60, wherein the presence, the absence or the recurrence of pelvic pain is reported by the subject on a visual analog scale (VAS).

### Claim 62 (depends on 60)

The method of claim 60, wherein the presence, the absence or the recurrence of pelvic pain is reported after the treatment is completed.

### Claim 63 (depends on 60)

The method of claim 60, wherein the pelvic pain comprises non-menstrual pelvic pain.

### Claim 64 (depends on 59)

The method of claim 59, wherein the identifying is based on the disease activity score.

### Claim 65 (depends on 57)

The method of claim 57, wherein the identifying is based at least in part on a medical history of the subject, a hormone receptor level of the subject, a mood of the subject, or any combination thereof.

### Claim 66 (depends on 57)

The method of claim 57, wherein the subject is identified as the responder with a sensitivity of at least about 80%.

### Claim 67 (depends on 57)

The method of claim 57, wherein the subject is identified as the responder with a specificity of at least about 80%.

### Claim 68 (depends on 60)

The method of claim 60, wherein the subject is identified as the non-responder with a sensitivity of at least about 80%.

### Claim 69 (depends on 60)

The method of claim 60, wherein the subject is identified as the non-responder with a specificity of at least about 80%.
